Zoetis Inc. $ZTS Shares Purchased by Central Bank & Trust Co.

Central Bank & Trust Co. raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 54.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,714 shares of the company’s stock after purchasing an additional 4,827 shares during the quarter. Central Bank & Trust Co.’s holdings in Zoetis were worth $1,725,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Halbert Hargrove Global Advisors LLC lifted its holdings in shares of Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares during the period. Global Wealth Strategies & Associates acquired a new position in Zoetis during the fourth quarter worth about $25,000. KERR FINANCIAL PLANNING Corp acquired a new position in Zoetis during the third quarter worth about $31,000. Holos Integrated Wealth LLC bought a new stake in Zoetis in the fourth quarter worth about $32,000. Finally, Board of the Pension Protection Fund bought a new stake in Zoetis in the fourth quarter worth about $38,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Down 0.3%

NYSE:ZTS opened at $115.31 on Tuesday. The stock has a fifty day simple moving average of $124.15 and a 200 day simple moving average of $130.02. The firm has a market capitalization of $48.68 billion, a price-to-earnings ratio of 19.15, a price-to-earnings-growth ratio of 1.77 and a beta of 0.95. Zoetis Inc. has a 1-year low of $114.36 and a 1-year high of $172.23. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter in the previous year, the company earned $1.40 EPS. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s payout ratio is currently 35.22%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, March 12th. William Blair reiterated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. HSBC set a $140.00 target price on shares of Zoetis in a research note on Wednesday, December 10th. UBS Group set a $136.00 target price on shares of Zoetis in a report on Thursday, January 29th. Finally, The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. Six investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.